Vol 30 No 9

New findings provide powerful evidence that inhibition of inflammation or its downstream effects on mood may open up a host of new approaches to treatment for depression, especially for patients with treatment-resistant depression.

Half of all mental health disorders occur by age 14. Early interventions may mitigate progression to more serious and persistent mental health concerns.

Older Latinos with depression report higher levels of impairment and are more persistently ill than non-Hispanic white older adults, yet they have lower rates of guideline-concordant treatment. Cognitive and problem-solving psychosocial modalities are emerging as key treatment considerations for older Latinos.

A risk to benefit ratio of treatment must be established to determine the optimal treatment for perimenopausal depression. Untreated depression during the perimenopause exacerbates heart disease, diabetes, and osteoporosis. Details about management options here.

Is depression a systemic disorder of oneself and the brain’s intrinsic activity?

For many patients with depression, full symptom remission remains elusive despite multiple trials of antidepressants. This article focuses on psychopharmacological and related interventions.

The diagnosis and management of unipolar depression remain challenging. The articles in this Special Report remind us of the wide knowledge base that is needed in the management of the depressed patient and of the multiple conceptual levels that must be integrated in the care of our patients.

Nonpharmacological interventions-such as mind-body interventions-can improve a partial response to antidepressants via stress reduction, improved physical functioning, increased socialization, and reduced risks of polypharmacy.

After all the encores at Tanglewood, the only music left is September’s song of crickets scraping their legs for mates...

What if someone with “prescriptive privileges” looked at superficial symptoms only, and ordered antipsychotics without considering the bigger picture?

This article summarizes efforts to develop neurocognitive enhancement drugs administered individually or as an adjunct to other antipsychotics and cognitive remediation.